# Amneal Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2021

- Company: [Amneal Pharmaceuticals, Inc.](/companies/amrx.md) (CIK 1723128)
- Form: 10-Q
- Filed: 2021-08-09
- Accepted by EDGAR: Aug 9, 2021, 16:05 ET
- Period: 2021-06-30
- Accession: 0001723128-21-000032
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1723128/000172312821000032/amrx-20210630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1723128/000172312821000032/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-04-01 to 2021-06-30 | $535.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2021-01-01 to 2021-06-30 | $1.03bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2021-04-01 to 2021-06-30 | $322.6m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2021-01-01 to 2021-06-30 | $624.1m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2021-04-01 to 2021-06-30 | $212.5m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2021-01-01 to 2021-06-30 | $404.1m | us-gaap:GrossProfit |
| Research and development | 3 months, 2021-04-01 to 2021-06-30 | $52.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2021-01-01 to 2021-06-30 | $101.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2021-04-01 to 2021-06-30 | $86.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2021-01-01 to 2021-06-30 | $176.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2021-04-01 to 2021-06-30 | $67.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2021-01-01 to 2021-06-30 | $113.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2021-04-01 to 2021-06-30 | $2.6m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2021-01-01 to 2021-06-30 | $3.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-04-01 to 2021-06-30 | $30.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2021-01-01 to 2021-06-30 | $42.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-04-01 to 2021-06-30 | $0.10 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2021-01-01 to 2021-06-30 | $0.14 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-04-01 to 2021-06-30 | $0.10 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2021-01-01 to 2021-06-30 | $0.14 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-04-01 to 2021-06-30 | 151,986,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2021-01-01 to 2021-06-30 | 151,606,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2021-01-01 to 2021-06-30 | $96.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2021-01-01 to 2021-06-30 | $19.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2021-06-30 | $278.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-06-30 | $1.56bn | us-gaap:AssetsCurrent |
| Total assets | at 2021-06-30 | $4.02bn | us-gaap:Assets |
| Current liabilities | at 2021-06-30 | $672.9m | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2021-06-30 | $2.72bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2021-06-30 | $30.5m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2021-06-30 | $346.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 48,864 characters.

Amneal Pharmaceuticals, Inc. (the “Company,” “we,” “us,” or “our”) is a pharmaceutical company specializing in developing, manufacturing, marketing and distributing high-value generic pharmaceutical products across a broad array of dosage forms and therapeutic areas, as well as branded products. We operate principally in the United States, India, and Ireland, and sell to wholesalers, distributors, hospitals, chain pharmacies and individual pharmacies, either directly or indirectly.

The following discussion and analysis contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth under Item 1A. Risk Factors in our 2020 Annual Report on Form 10-K and under the heading *Cautionary Note Regarding Forward-Looking Statements* included elsewhere in this Quarterly Report on Form 10-Q.

The following discussion and analysis for the three and six months ended June 30, 2021 should also be read in conjunction with the consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements for the year ended December 31, 2020 included in our 2020 Annual Report on Form 10-K.

### Overview

We have three reportable segments: Generics, Specialty, and AvKARE.

#### Generics

Our Generics segment includes approximately 250 product families covering an extensive range of dosage forms and delivery systems, including both immediate and extended release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, ophthalmics (which are sterile pharmaceutical preparations administered for ocular conditions), films, transdermal patches and topicals (which are creams or gels designed to administer pharmaceuticals locally through the skin). We focus on developing products with substantial barriers-to-entry resulting from complex drug formulations or manufacturing, or legal or regulatory challenges. Generic products, particularly in the U.S., generally contribute most significantly to revenues and gross margins at the time of their launch, and even more so in periods of market exclusivity, or in periods of limited generic competition. As such, the timing of new product introductions can have a significant impact on the Company’s financial results. The entrance into the market of additional competition generally has a negative impact on the volume and / or pricing of the affected products. Additionally, pricing is determined by market place dynamics and is often affected by factors outside of the Company’s control.

#### Specialty

Our Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system (“CNS”) disorders, including migraine and Parkinson’s disease. Our portfolio of products includes Rytary®, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. In addition to Rytary®, our promoted Specialty portfolio includes Unithroid® (levothyroxine sodium), for the treatment of hypothyroidism, which is sold under a license and distribution agreement with Jerome Stevens Pharmaceuticals, Inc., Emverm® (mebendazole) 100 mg chewable tablets, for the treatment of pinworm, whipworm, common roundworm, common hookworm and American hookworm in single or mixed infections, and Zomig® (zolmitriptan) products, for the treatment of migraine headaches, which is sold under a license agreement with AstraZeneca U.K. Limited. We believe that we have the research, development and formulation expertise to develop branded products that will deliver significant improvements over existing therapies.

For Specialty products, the majority of the product’s commercial value is usually realized during the period in which the product has market exclusivity. In the U.S. when market exclusivity expires and generic versions of a product are approved and marketed, there can often be very substantial and rapid declines in the branded product’s sales. For example, due to its patent expiration in May 2021, we recently lost market exclusivity for Zomig® Spray. Although no generic product has been commercially launched in the United States as of June 30, 2021, we anticipate competition in the future.

#### AvKARE

Our AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. AvKARE is a re-packager of bottle and unit dose pharmaceuticals under the registered names of AvKARE and AvPAK, which service the Department of Defense and Department of Veterans Affairs as well as institutional customers. AvKARE is also a wholesale distributor of pharmaceuticals, over the counter products and medical supplies to institutional customers which are located throughout the United States of America focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing.

#### The Pharmaceutical Industry

The pharmaceutical industry is highly competitive and highly regulated. As a result, we face a number of industry-specific factors and challenges, which can significantly impact our results. For a more detailed explanation of our business and its risks, refer to our *2020 Annual Report on Form 10-K,* as supplemented by Part II, Item 1A “Risk Factors” of our subsequent Quarterly Reports on Form 10-Q.

#### COVID-19 Pandemic

On March 11, 2020, the World Health Organization designated the outbreak of a novel strain of coronavirus (“COVID-19”) as a global pandemic. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including imposing restrictions on movement and travel such as quarantines and shelter-in-place requirements, and restricting or prohibiting outright some or all commercial and business activity, including the manufacture and distribution of certain goods and the provision of non-essential services. These measures, though currently temporary in nature, may become more severe and continue indefinitely depending on the evolution of the outbreak.

We observed lost sales and some supply interruptions during the year ended December 31, 2020 in our New York, New Jersey and India manufacturing plants. Additionally, decreased influenza activity during the six months ended June 30, 2021 drove significantly lower sales volume and increased returns related to Oseltamivir as compared to the prior year period.

While manufacturing has resumed to around pre-COVID-19 levels, we may again experience supply chain constraints at our New York, New Jersey, India or other facilities during subsequent waves of COVID-19 infections. Any potential supply chain disruptions may significantly impact our 2021 results of operations and cash flows. Several of our key domestic manufacturing, packaging, and facilities are located in New York and New Jersey, two states with a high number of confirmed cases of COVID-19. Additionally, we have key international manufacturing and research and development facilities in India, a country with a high number of confirmed cases of COVID-19.

To the extent that the COVID-19 pandemic continues or worsens, national, state, local and international governments may impose additional restrictions or extend the restrictions already in place. The worsening of the pandemic and the related safety and business operating restrictions could result in a number of adverse impacts to our business, including, but not limited to, additional disruption to the economy and our customers, additional work restrictions, supply chains being interrupted or slowed, and rising supply prices. Also, governments may impose other laws, regulations, or taxes that could adversely impact our business, financial condition, or results of operations. Further, depending on the extent to which our customers are affected, they could delay or reduce purchases of products we provide. The potential effects of the COVID-19 pandemic also could impact us in a number of other ways including, but not limited to, reductions to our profitability, fluctuations in foreign currency markets, the availability of future borrowings, the cost of borrowings, credit risks of our customers and counterparties, and potential impairment of the carrying amount of goodwill or other definite-lived assets.

We continue to actively monitor the situation and may take further precautionary and preemptive actions as may be required by national, state, or local authorities or that we determine are in the best interests of our employees, customers, partners, suppliers, and shareholders. Until the ultimate extent and duration of the pandemic is known, we cannot predict the ultimate effects the pandemic may have on our business, in particular with respect to demand for our products, our strategy, and our prospects, the effects on our customers, or the impact on our financial results.

#### Inflation

While it is difficult to accurately measure the impact of inflation, we believe our business has not been significantly impacted by the overall effects of inflation to date. However, rising inflationary pressures due to higher input costs, including higher material, transportation, labor and other costs, may affect us as well as our vendors and may adversely impact our operating results in future periods.

### Results of Operations

### Consolidated Results

The following table sets forth our summarized, consolidated results of operations for the three and six months ended June 30, 2021 and 2020 (in thousands):

|  | Three Months Ended June 30, 2021 | 2020 | Six Months Ended June 30, 2021 | 2020 |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $535,075 | $464,662 | $1,028,180 | $963,195 |
| Cost of goods sold | 322,577 | 319,666 | 624,120 | 633,244 |
| Cost of goods sold impairment charges | — | 759 | — | 2,215 |
| **Gross profit** | 212,498 | 144,237 | 404,060 | 327,736 |
| Selling, general and administrative | 86,157 | 80,944 | 176,883 | 158,920 |
| Research and development | 52,864 | 45,572 | 101,046 | 81,951 |
| In-process research and development impairment charges | 710 | — | 710 | 960 |
| Intellectual property legal development expenses | 1,365 | 3,550 | 4,947 | 4,820 |
| Acquisition, transaction-related and integration expenses | 4,283 | 1,787 | 7,085 | 4,362 |
| Charges related to legal matters, net | — | 1,300 | — | 5,800 |
| Restructuring and other charges | — | 333 | 363 | 2,381 |
| **Operating income** | 67,119 | 10,751 | 113,026 | 68,542 |
| Total other expense, net | (32,295) | (32,509) | (63,298) | (76,956) |
| Income (loss) before income taxes | 34,824 | (21,758) | 49,728 | (8,414) |
| Provision for (benefit from) income taxes | 2,648 | 2,186 | 3,007 | (105,987) |
| **Net income (loss)** | $32,176 | $(23,944) | $46,721 | $97,573 |

#### Net Revenue

Net revenue for the three months ended June 30, 2021 increased by 15%, or $70 million, to $535 million as compared to $465 million for the three months ended June 30, 2020. The increase from the prior year period was attributable to the following:

- Our Generics segment revenues of $360 million grew $54 million from the prior year period, which was primarily due to new products launched in 2020 and 2021 that contributed revenue growth of $61 million. In addition, there was overall volume growth within the Generics and AvKARE segments, in part due to an increase of customer purchases at the onset of the COVID-19 pandemic during the three months ended March 31, 2020, which contributed to lower volume in those segments during the three months ended June 30, 2020. The overall increase during the three months ended June 30, 2021 compared to the prior year period was partially offset by a $10 million decline in Oseltamivir (generic Tamiflu®) sales from lower demand and increase returns activity above historical levels due to decreased influenza activity during the COVID-19 pandemic, as well as erosion in our base business.
- Growth in our AvKARE segment revenues of $22 million primarily related to organic growth due to better new product introductions and the impact from COVID-19, as discussed above.
- Our Specialty segment revenues of $89 million decreased $6 million from the prior year period, primarily attributed to a decline in non-promoted Specialty brands. Offsetting this decrease includes an increase in revenue of Rytary® and Unithroid®.

Net revenue for the six months ended June 30, 2021 increased by 7%, or $65 million, to $1,028 million as compared to $963 million for the six months ended June 30, 2020. The increase from the prior year period was attributable to growth in all three operating segments as follows:

- Our AvKARE segment revenues of $171 million grew $49 million versus the prior year period, in part due to the timing of acquisition in 2020 as well as organic growth due to better new product introductions.
- Growth in our Generics segment of $14 million was primarily due to new products launched in 2020 and 2021 that contributed revenue growth of $97 million, as well as volume growth in the base business. This increase was partially offset by a $33 million decline in Oseltamivir (generic Tamiflu®) sales from lower demand and increased returns activity above historical levels that were due to decreased influenza activity during the COVID-19 pandemic, and price erosion in our base business.
- Our Specialty segment revenues increased $2 million, reflecting growth in Rytary® and Unithroid® of $9 million, partially offset by declines in Zomig® nasal spray and other non-promoted products.

#### Cost of Goods Sold and Gross Profit

Cost of goods sold, including impairment charges, increased 1%, or $2 million, to $323 million for the three months ended June 30, 2021 as compared to $320 million for the three months ended June 30, 2020. The increase in cost of goods sold was primarily attributable to an increase in revenue as noted above, offset in part by gross margin improvement due to reduced material costs, better plant utilization including manufacturing a higher percentage of the Company’s products, and favorable product mix.

Gross profit for the three months ended June 30, 2021 was $212 million (40% of total net revenue) as compared to gross profit of $144 million (31% of total net revenue) for the three months ended June 30, 2020. Our gross profit as a percentage of net revenue increased compared to the prior year period primarily as a result of the factors noted above.

Cost of goods sold, including impairment charges, decreased 2%, or $11 million, to $624 million for the six months ended June 30, 2021 as compared to $635 million for the six months ended June 30, 2020. The decrease in cost of goods sold was primarily attributable to gross margin improvement, which was related to reduced material costs, better plant utilization including manufacturing a higher percentage of the Company’s products, and favorable product mix. Partially offsetting this decrease was an extra month of AvKARE expense, as well as an increase in revenues for the comparative period.

Gross profit for the six months ended June 30, 2021 was $404 million (39% of total net revenue) as compared to gross profit of $328 million (34% of total net revenue) for the six months ended June 30, 2020. Our gross profit as a percentage of net revenue increased compared to the prior year period primarily as a result of the factors noted above.

#### Selling, General, and Administrative

Selling, general, and administrative (“SG&A”) expenses for the three months ended June 30, 2021 were $86 million, as compared to $81 million for the three months ended June 30, 2020. The $5 million increase from the prior year period was primarily due to an increase in employee compensation, and an increase in third party spend and promotional efforts as the Company began to resume normal activities and in-person meetings in the current year. This increase was partially offset by a reduction in costs to exit redundancies in connection with Company’s integration efforts of recent business acquisitions.

Selling, general, and administrative (“SG&A”) expenses for the six months ended June 30, 2021 were $177 million, as compared to $159 million for the six months ended June 30, 2020. The $18 million increase from the prior year period was primarily due to an increase in employee compensation, an extra month of expenses from our AvKARE segment and an increase in indirect taxes.

#### Research and Development

Research and development (“R&D”) expenses for the three months ended June 30, 2021 was $53 million, as compared to $46 million for the three months ended June 30, 2020. The $7 million increase compared to the prior year period was primarily attributable to increased in-licensing and upfront milestone payments of $1 million to grow our Specialty and Generics pipelines, and increased project spend for ongoing project costs, including $3 million related to projects acquired in the acquisition of Kashiv Specialty Pharmaceuticals, LLC (the “KSP Acquisition”). Refer to *Note 3. Acquisitions* for additional information.

R&D expenses for the six months ended June 30, 2021 were $101 million, as compared to $82 million for the six months ended June 30, 2020. The $19 million increase compared to the prior year period was primarily attributable to an increased in-licensing and upfront milestone payments of $10 million to grow our Specialty and Generics pipelines and increased project spend for ongoing project costs associated with IPX203 and complex generic product candidates, as well as $3 million related to projects acquired in the KSP Acquisition.

#### Intellectual Property Legal Development Expense

Intellectual property legal development expenses include, but are not limited to, costs associated with formulation assessments, patent challenge opinions and strategy, and litigation expenses to defend our intellectual property. Intellectual property legal development expenses for the three months ended June 30, 2021 were $1 million as compared to $4 million for the three months ended June 30, 2020. The decrease in expenses from the prior year period related to an decrease in the number of individual cases and corresponding litigation from the comparative period. Intellectual property legal development expenses for both the six months ended June 30, 2021 and 2020 were $5 million.

#### Acquisition, Transaction-Related and Integration Expenses

Acquisition, transaction-related and integration expenses were $4 million for the three months ended June 30, 2021 as compared to $2 million for the three months ended June 30, 2020. Acquisition, transaction-related and integration expenses were $7 million for the six months ended June 30, 2021 as compared to $4 million for the six months ended June 30, 2020.

Expenses for the three and six months ended June 30, 2021 were primarily related to the KSP Acquisition, which closed on April 2, 2021, and the related integration, and the integration of the Rondo Acquisitions. For the three and six months ended June 30, 2020, acquisition, transaction-related and integration expenses were primarily related to the acquisition and integration of the businesses that comprise our AvKARE segment and system integration expenses related to the combination with Impax Laboratories, LLC. Refer to *Note 3. Acquisitions* for additional information.

#### Charges Related to Legal Matters, Net

There were no net charges related to legal matters, net for both the three and six months ended June 30, 2021. For the three months ended June 30, 2020, we recorded a net charge of $1 million, approximately $3 million of which was recorded in our Generics segment and was partially offset by a $2 million gain in our Specialty segment.

For the six months ended June 30, 2020, we recorded a net charge of $6 million, the majority of which was recorded in our Generics segment.

#### Restructuring and Other Charges

On July 10, 2019, we announced a plan to restructure our operations that is intended to reduce costs and optimize our organizational and manufacturing infrastructure. Pursuant to the restructuring plan as revised, we expect to reduce our headcount by approximately 300 to 350 by June 30, 2022, primarily by closing our manufacturing facility located in Hauppauge, NY. Through June 30, 2021, the Company had reduced headcount by 280 employees under this plan.

Restructuring and other charges were $0.3 million for the three months June 30, 2020 (none for the three months ended June 30, 2021). Restructuring and other charges were $0.4 million and $2 million for the six months ended June 30, 2021 and 2020, respectively. These charges primarily consisted of the cost of benefits provided pursuant to our severance programs for former senior executives and management employees.

#### Other Expense, Net

Other expense, net was $32 million for the three months ended June 30, 2021, compared to $33 million for the three months ended June 30, 2020. Overall, the $1 million decrease was driven by a $3 million decline in interest expense due to a reduction in interest rates compared to the prior period and a $4 million benefit relating to a previously outstanding contingent liability, partially offset by a $6 million unfavorable period-over-period impact of net foreign exchange gains and losses.

Other expense, net was $63 million for the six months ended June 30, 2021, as compared to $77 million for the three months ended June 30, 2020. The decrease of $14 million was primarily due to a $9 million decline in interest expense due to a reduction in interest rates compared to the prior year period, a $4 million benefit relating to a previously outstanding contingent liability and a $2 million favorable period-over-period impact of net foreign exchange gains and losses.

#### Provision For (Benefit From) Income Taxes

For the three months ended June 30, 2021 and 2020, our provision for income taxes and effective tax rates were $3 million and 7.6%, respectively, compared to $2 million and (10.0)%, respectively, for the three months ended June 30, 2020.

For the six months ended June 30, 2021 and 2020, our provision for (benefit from) income taxes and effective tax rates were $3 million and 6.0%, respectively, compared to $(106) million and 1259.7%, respectively, for the six months ended June 30, 2020.

The income tax benefit for the six months ended June 30, 2020 was primarily impacted by a $110 million carryback of U.S. Federal net operating losses under the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”). The CARES Act was an emergency economic stimulus package in response to the COVID-19 pandemic which, among other things, includes provisions relating to income and non-income-based tax laws. For further details, refer to *Note 7. Income Taxes.*

#### Net Income

We recognized net income for the three months ended June 30, 2021 of $32 million as compared to net loss of $24 million for the three months ended June 30, 2020. The year-over-year increase in net income of $56 million was attributable to the factors listed above.

We recognized net income for the six months ended June 30, 2021 of $47 million as compared to net income of $98 million for the six months ended June 30, 2020. The year-over-year decrease in net income of $51 million was attributable to the factors listed above, most notably the tax benefit from a $110 million carryback of U.S. Federal net operating losses under the CARES Act in the prior year period.

### Generics

The following table sets forth results of operations for our Generics segment for the three and six months ended June 30, 2021 and 2020 (in thousands):

|  | Three Months Ended June 30, 2021 | 2020 | Six Months Ended June 30, 2021 | 2020 |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $360,437 | $306,559 | $672,945 | $659,145 |
| Cost of goods sold | 204,154 | 218,909 | 389,452 | 437,774 |
| Cost of goods sold impairment charges | — | 759 | — | 2,215 |
| **Gross profit** | 156,283 | 86,891 | 283,493 | 219,156 |
| Selling, general and administrative | 11,797 | 12,802 | 30,559 | 29,425 |
| Research and development | 43,431 | 40,316 | 79,548 | 69,350 |
| In-process research and development impairment charges | 710 | — | 710 | 960 |
| Intellectual property legal development expenses | 1,340 | 3,550 | 4,922 | 4,815 |
| Acquisition, transaction-related and integration expenses | — | 324 | — | 324 |
| Charges related to legal matters, net | — | 3,050 | — | 5,550 |
| Restructuring and other charges | — | 333 | 80 | 379 |
| **Operating income** | $99,005 | $26,516 | $167,674 | $108,353 |

#### Net Revenue

Generics net revenue was $360 million for the three months ended June 30, 2021, an increase of $54 million or 18% when compared with the same period in 2020. The increase from the prior year period was attributable to new products launched in 2020 and 2021, which contributed revenue growth of approximately $61 million. We also experienced volume growth in part due to an increase in customer purchases at the onset of the COVID-19 pandemic during the three months ended March 31, 2020, including supply chain disruptions during the three months ended June 30, 2020, which contributed to overall lower volume in the corresponding prior year period. The increase was partially offset by a $10 million decline in Oseltamivir (generic Tamiflu®) sales from lower demand and increased returns activity above historical levels due to decreased influenza activity during the COVID-19 pandemic, as well as erosion in our base business.

Generics net revenue was $673 million for the six months ended June 30, 2021, an increase of $14 million or 2% when compared with the same period in 2020. The increase primarily related to new products launched in 2020 and 2021 which contributed revenue growth of $97 million, as well as volume growth in our base business. This increase was partially offset by a $33 million decline in Oseltamivir (generic Tamiflu®) sales from lower demand and increased returns activity above historical levels due to decreased influenza activity during the COVID-19 pandemic, and price erosion in our base business.

#### Cost of Goods Sold and Gross Profit

Generics cost of goods sold, including impairment charges, for the three months ended June 30, 2021 was $204 million, a decrease of 7% or $16 million compared to the three months ended June 30, 2020. The decrease in cost of goods sold was primarily attributable to gross margin improvement due to reduced material costs, better plant utilization and manufacturing a higher percentage of the Company’s products, and favorable product mix.

Generics gross profit for the three months ended June 30, 2021 was $156 million (43% of net revenue) as compared to gross profit of $87 million (28% of net revenue) for the three months ended June 30, 2020 as a result of the factors described above.

Generics cost of goods sold, including impairment charges, for the six months ended June 30, 2021 was $389 million, a decrease of 11% or $51 million compared to the six months ended June 30, 2020. The decrease in cost of goods sold was primarily attributable to gross margin improvement due to reduced material costs, better plant utilization and manufacturing a higher percentage of the Company’s products, a more favorable product mix, and a $2 million decrease in intangible asset impairments.

Generics gross profit for the six months ended June 30, 2021 was $283 million (42% of net revenue) as compared to gross profit of $219 million (33% of net revenue) for the six months ended June 30, 2020 as a result of the factors described above.

#### Selling, General, and Administrative

Generics SG&A expense for the three months ended June 30, 2021 was $12 million, as compared to $13 million for the three months ended June 30, 2020. The $1 million decrease from the prior year period was primarily related to a reduction in costs to exit redundancies in connection with Company’s integration efforts of recent business acquisitions.

Generics SG&A expense for the six months ended June 30, 2021 was $31 million, as compared to $29 million for the six months ended June 30, 2020. The increase was primarily attributed to increased employee compensation and an increase in indirect taxes, partially offset by a reduction in costs to exit redundancies in connection with Company’s integration efforts of recent business acquisitions.

#### Research and Development

Generics R&D expenses for the three months ended June 30, 2021 was $43 million, an increase of 8% or $3 million compared to the three months ended June 30, 2020. The year-over-year increase was primarily attributable to an increase of in-licensing and upfront milestone payments of $1 million and an increase in employee compensation.

Generics R&D expenses for the six months ended June 30, 2021 was $80 million, an increase of 15% or $10 million compared to the six months ended June 30, 2020. The $10 million increase year-over-year increase was primarily associated an increase with in-licensing and upfront milestone payments of $5 million, an increase in employee compensation, and increased project spend on complex generics.

#### Intellectual Property Legal Development Expenses

Intellectual property legal development expenses include, but are not limited to, costs associated with formulation assessments, patent challenge opinions and strategy, and litigation expenses to defend our intellectual property. Intellectual property legal development expenses for the three months ended June 30, 2021 were $1 million as compared to $4 million for the three months ended June 30, 2020. The decrease in expenses from the prior year period related to the number of individual cases and corresponding litigation. Intellectual property legal development expenses for the each of the six-month periods ended June 30, 2021 and 2020 were $5 million.

#### Charges Related to Legal Matters, Net

There were no charges related to legal matters for the three and six months ended June 30, 2021. For the three and six months ended June 30, 2020, we recorded a net charge of $3 million and $6 million, respectively, for commercial legal claims.

### Specialty

The following table sets forth results of operations for our Specialty segment for the three and six months ended June 30, 2021 and 2020 (in thousands):

|  | Three Months Ended June 30, 2021 | 2020 | Six Months Ended June 30, 2021 | 2020 |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $88,635 | $94,256 | $184,566 | $182,233 |
| Cost of goods sold | 48,683 | 50,229 | 96,881 | 98,047 |
| **Gross profit** | 39,952 | 44,027 | 87,685 | 84,186 |
| Selling, general and administrative | 20,656 | 16,870 | 40,537 | 37,812 |
| Research and development | 9,433 | 5,256 | 21,498 | 12,601 |
| Intellectual property legal development expenses | 25 | — | 25 | 5 |
| Acquisition, transaction-related and integration expenses | 16 | 82 | 16 | 82 |
| Charges related to legal matters, net | — | (1,750) | — | 250 |
| **Operating income** | $9,822 | $23,569 | $25,609 | $33,436 |

#### Net Revenue

Specialty net revenue for the three months ended June 30, 2021 was $89 million, a decrease of $6 million, or 6%, compared to the three months ended June 30, 2020. The overall growth in demand for our promoted products Rytary® and Unithroid® was offset by anticipated declines in Zomig® nasal spray due to loss of market exclusivity in the current quarter, and declines among other non-promoted products.

Specialty net revenue for the six months ended June 30, 2021 was $185 million, an increase of $2 million, or 1% compared to the six months ended June 30, 2020. The increase reflected growth in Rytary® and Unithroid® of $9 million, which was partially offset by declines in Zomig® nasal spray and other non-promoted products.

#### Cost of Goods Sold and Gross Profit

Specialty cost of goods sold for the three months ended June 30, 2021 was $49 million as compared to $50 million for the three months ended June 30, 2020. Specialty gross profit for the three months ended June 30, 2021 was $40 million (45% of net revenue) as compared to gross profit of $44 million (47% of net revenue) for the three months ended June 30, 2020. The decrease in gross profit primarily related to the mix of revenues, including the impact of non-promoted products.

Specialty cost of goods sold for of the six months ended June 30, 2021 was $97 million as compared to $98 million the six months ended June 30, 2020. Specialty gross profit for the six months ended June 30, 2021 was $88 million (48% of net revenue) as compared to gross profit of $84 million (46% of net revenue) for the six months ended June 30, 2020. The increase in gross profit primarily related to the mix of revenues, including the impact of non-promoted products. Additionally, the increase in gross margin was due to growth in higher margin products offsetting declines in Zomig® nasal spray, which has a higher cost structure than the overall Specialty portfolio.

#### Selling, General, and Administrative

Specialty SG&A expense was $21 million for the three months ended June 30, 2021, an increase of $4 million or 22% compared to the three months ended June 30, 2020. The increase was primarily driven by an increase in employee compensation mainly due to additional headcount in our endocrinology sales force, and an increase in third party spend and promotional efforts as the Company began to resume normal activities and in-person meetings in the current year.

Specialty SG&A expense was $41 million for the six months ended June 30, 2021, an increase of $3 million or 7% compared to the six months ended June 30, 2020. The increase was driven by an increase in indirect taxes and payroll-related expenses, primarily attributable to the expansion of our sales force.

#### Research and Development

Specialty R&D expenses for the three months ended June 30, 2021 were $9 million, as compared to $5 million for the three months ended June 30, 2020. The $4 million increase from the prior year period was primarily attributable to increased project spend, including $3 million relating to new projects associated with the KSP Acquisition.

Specialty R&D expenses for the six months ended June 30, 2021 were $21 million, as compared to $13 million for the six months ended June 30, 2020. The $9 million increase from the prior year period was primarily attributable to an increase in in-licensing and upfront milestone payments of $5 million to grow our Specialty pipeline and increased project spend, including $3 million relating to new projects associated with the KSP Acquisition.

#### Charges Related to Legal Matters, Net

There were no charges related to legal matters for the three and six months ended June 30, 2021. For the three months ended June 30, 2020, Specialty recorded a gain of $2 million for the favorable resolution of commercial legal proceedings. For the six months ended June 30, 2020, charges related to legal matters, net were immaterial.

### AvKARE

The following table sets forth results of operations for our AvKARE segment for the three and six months ended June 30, 2021 and 2020 (in thousands):

|  | Three Months Ended June 30, 2021 | 2020 | Six Months Ended June 30, 2021 | 2020 |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $86,003 | $63,847 | $170,669 | $121,817 |
| Cost of goods sold | 69,740 | 50,528 | 137,787 | 97,423 |
| **Gross profit** | 16,263 | 13,319 | 32,882 | 24,394 |
| Selling, general and administrative | 13,599 | 15,647 | 27,303 | 26,435 |
| Acquisition, transaction-related and integration expenses | 491 | — | 1,422 | — |
| **Operating income (loss)** | $2,173 | $(2,328) | $4,157 | $(2,041) |

We completed the acquisitions of the businesses that comprise our AvKARE segment on January 31, 2020. As a result, the increase in results of operations for the AvKARE segment was primarily due to six months of activity in 2021 as compared to five months of activity in 2020 The following discussion specifically is for operating results for the comparative three months ended June 30, 2021 and 2020. Refer to *Note 3. Acquisitions*, for additional information on the acquisitions.

#### Net Revenue

AvKARE net revenue for the three months ended June 30, 2021 was $86 million, an increase of $22 million, or 35%, compared to the three months ended June 30, 2020. The overall increase related to organic growth due to better new product introductions and unfavorable timing of revenue in the prior year period due to COVID-19 that benefited the three months ended September 30, 2020.

#### Cost of Goods Sold and Gross Profit

AvKARE cost of goods sold for the three months ended June 30, 2021 was $70 million as compared to $51 million for the three months ended June 30, 2020. AvKARE gross profit for the three months ended June 30, 2021 was $16 million (19% of net revenue) as compared to gross profit of $13 million (21% of net revenue) for the three months ended June 30, 2020. The increase in gross profit primarily related to organic growth due to new product introductions. Gross margin decreased from the prior period primarily due to price erosion within the existing portfolio.

#### Selling, General, and Administrative

AvKARE SG&A expense was $14 million for the three months ended June 30, 2021, a decrease of $2 million or 13% compared to the three months ended June 30, 2020. The decrease was primarily related to a reduction in redundant costs as the Company’s integration efforts related to the acquisition of the businesses comprising our AvKARE segment (the “Rondo Acquisitions”) in the prior year period.

### Liquidity and Capital Resources

Our primary source of liquidity is cash generated from operations, available cash on hand and borrowings under debt financing arrangements, including $498 million of available capacity on our revolving credit facility as of June 30, 2021. Refer to *Note 17. Debt* in our 2020 Annual Report on Form 10-K for additional information. We believe these sources are sufficient to fund our planned operations, meet our interest and contractual obligations and provide sufficient liquidity over the next 12 months from the date of filing of this Form 10-Q. However, our ability to satisfy our working capital requirements and debt obligations will depend upon economic conditions, the impact of the COVID-19 pandemic, and demand for our products, which are factors that may be out of our control.

Our primary uses of capital resources are to fund operating activities, including research and development expenses associated with new product filings, and pharmaceutical product manufacturing expenses, license payments, spending on production facility expansions and capital equipment, and acquisitions. As the impact of the COVID-19 pandemic on the economy and our operations evolves, we will continue to assess our liquidity needs. A continued worldwide disruption could materially affect our future access to sources of liquidity, particularly our cash flows from operations, and financial condition. In the event of a sustained market deterioration, we may need additional liquidity, which would require us to evaluate available alternatives and take appropriate actions.

We estimate that we will invest approximately $60 million to $70 million during 2021 for capital expenditures to support and grow our existing operations, primarily related to investments in manufacturing equipment, information technology and facilities. As discussed in *Note. 3 Acquisitions*, the KSP Acquisition closed on April 2, 2021. Under the terms of the acquisition, in addition to the cash paid at closing, we are required to make a cash payment of $30 million on January 11, 2022.

Refer to *Note 17. Debt* in our 2020 Annual Report on Form 10-K for detailed information, including definitions, of our loans. We will make substantial payments for monthly interest and quarterly principal amounts due on our Term Loan and Rondo Term Loan. Related to our Term Loan, we were required to calculate the amount of excess cash flows based on our results for the year ended December 31, 2020. As a result, we made a payment of $14 million in March 2021 to satisfy the excess cash flow requirements, in addition to our normal principal payments. Accordingly, we expect to make $41 million in principal payments and make interest payment payments totaling $112 million during 2021 related to our Term Loan. Related to our Rondo Term Loan, we expect to make $9 million in principal payments and make interest payments totaling $6 million during 2021. Additionally, we fully repaid the Short-Term Sellers Note of $1 million during February 2021.

We are party to a tax receivable agreement (“TRA”) that requires us to make cash payments to APHC Holdings LLC (formerly known as Amneal Holdings LLC) (“Holdings”) in respect of certain tax benefits that we may realize or may be deemed to realize as a result of sales or exchanges of Amneal common units by Holdings. The timing and amount of any payments under the TRA will also vary, depending upon a number of factors including the timing and number of Amneal common units sold or exchanged for our class A Common Stock, the price of our class A Common Stock on the date of sale or exchange, the timing and amount of our taxable income, and the tax rate in effect at the time of realization of our taxable income. The tax receivable agreement also requires that we make an accelerated payment to Holdings equal to the present value of all future payments due under the agreement upon certain change of control and similar transactions. Further sales or exchanges occurring subsequent to June 30, 2021 could result in future Amneal tax deductions and obligations to pay 85% of such benefits to the holders of Amneal common units. These obligations could be incremental to and substantially larger than the approximate $206 million contingent liability as of June 30, 2021 (refer to *Note 7. Income Taxes*). As a result of the foregoing, our obligations under the tax receivable agreement could have a substantial negative impact on our liquidity. For further details, refer to *Item 1A. Risk Factors* and *Note 8. Income Taxes* in our 2020 Annual Report on Form 10-K.

In addition, pursuant to the limited liability operating agreement of Amneal, as amended, in connection with any tax period, we will be required to make distributions to Amneal's members, on a pro rata basis in proportion to the number of Amneal Common Units held by each member, of cash until each member (other than Amneal) has received an amount at least equal to its assumed tax liability and Amneal has received an amount sufficient to enable it to timely satisfy all of its U.S. federal, state and local and non-U.S. tax liabilities, and meet its obligations pursuant to the tax receivable agreement. During the six months ended June 30, 2021, we made tax distributions of $26 million to Amneal's members.

At June 30, 2021, our cash and cash equivalents consist of cash on deposit and highly liquid investments. A portion of our cash flows are derived outside the United States. As a result, we are subject to market risk associated with changes in foreign exchange rates. We maintain cash balances at both U.S. based and foreign country based commercial banks. At various times during the year, our cash balances held in the United States may exceed amounts that are insured by the Federal Deposit Insurance Corporation (FDIC). We make our investments in accordance with our investment policy. The primary objectives of our investment policy are liquidity and safety of principal.

### Cash Flows

#### (in thousands)

| Cash provided by (used in): | Six Months Ended June 30, 2021 | 2020 |
| --- | ---: | ---: |
| Operating activities | $96,195 | $228,267 |
| Investing activities | (95,580) | (270,969) |
| Financing activities | (64,217) | 157,897 |
| Effect of exchange rate changes on cash | (366) | 255 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | $(63,968) | $115,450 |

#### Cash Flows from Operating Activities

Net cash provided by operating activities was $96 million for the six months ended June 30, 2021 as compared to $228 million for the six months ended June 30, 2020. The $132 million decrease in net cash provided by operating activities for the six months ended June 30, 2021 as compared to the prior year period was primarily driven by the unfavorable timing of cash collections on trade receivables in large part due to timing impacts of certain pricing initiatives and timing of rebate payments, an increase in inventory levels that decreased during the COVID-19 outbreak in 2020, increased payments for in-licensing and milestones and other working capital increases. Net cash paid for income taxes during the six months ended June 30, 2021 compared to the prior year was essentially flat. There was no cash income tax benefit from the carryback of Federal net operating losses associated with the CARES Act in the prior year until the three months ended September 30, 2020.

#### Cash Flows from Investing Activities

Net cash used in investing activities for the six months ended June 30, 2021 was $96 million as compared to $271 million for the six months ended June 30, 2020. The $175 million decrease in net cash used in investing activities for the six months ended June 30, 2021 as compared to the prior year period was due to $254 million of net cash paid for the Rondo Acquisitions in the prior year period as compared to $74 million of net cash paid for the KSP Acquisition in the current year period. The overall decrease was partially offset by an increase in cash payments for purchases of property, plant and equipment in the current year period. Refer to *Note 3. Acquisitions*, for additional information on our acquisitions.

#### Cash Flows from Financing Activities

Net cash used in financing activities was $64 million for the six months ended June 30, 2021 as compared to net cash provided by financing activities of $158 million for the six months ended June 30, 2020. The change was primarily attributable to net proceeds from a $180 million term loan associated with the Rondo Acquisitions in the prior year period, which was partially offset by tax distributions of $28 million made to non-controlling interests in the current year and an increase in principal payments related to debt and financing leases in the current year, primarily related to $14 million paid in March 2021 to satisfy the excess cash flow requirements. Refer to *Note 3. Acquisitions*, for additional information on our acquisitions. Refer to *Note 17. Debt* in our 2020 Annual Report on Form 10-K for detailed information about our indebtedness, including definitions of terms.

### Commitments and Contractual Obligations

The contractual obligations of the Company are set forth in *Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations* contained in the Company’s 2020 Annual Report on Form 10-K. Other than the contractual obligations noted below, there have been no material changes to the disclosure presented in our 2020 Annual Report on Form 10-K.

| Contractual Obligations | Payments Due by Period Total | Less Than 1 Year | 1-3 Years | 3-5 Years | More Than 5 Years |
| --- | ---: | ---: | ---: | ---: | ---: |
| Kashiv Specialty Pharmaceuticals, LLC acquisition | $30,500 | $30,500 | $— | $— | $— |

The foregoing table does not include contingent consideration liabilities as it relates to the KSP Acquisition. Such milestone payments are dependent upon the occurrence of specific and contingent events, and not the passage of time. Refer to *Note 3. Acquisitions* and *Note 10. Fair Value Measurements* for additional information.

### Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of June 30, 2021.

### Critical Accounting Policies

For a discussion of the Company’s critical accounting policies, see *Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations* in our 2020 Annual Report on Form 10-K. There have been no material changes to the disclosures presented in our 2020 Annual Report on Form 10-K, except those discussed in *Note 2. Summary of Significant Accounting Policies.*

### Recently Issued Accounting Standards

Recently issued accounting standards are discussed in *Note 2. Summary of Significant Accounting Policies.*

## Market risk

As filed, 198 characters.

There has not been any material change in our assessment of market risk as set forth in *Item 7A. Quantitative and Qualitative Disclosures About Market Risk*, in our 2020 Annual Report on Form 10-K.

## Controls and procedures

As filed, 2,875 characters.

### Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) that are designed to ensure information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Co-Chief Executive Officers and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Co-Chief Executive Officers and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Co-Chief Executive Officers and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2021.

### Changes in Internal Control over Financial Reporting

During the quarter ended June 30, 2021, there were no changes in our internal control over financial reporting which materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Limitations on the Effectiveness of Controls

Management, including our Co-Chief Executive Officers and Chief Financial Officer, does not expect that our disclosure controls and procedures or our system of internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed or operated, can provide only reasonable, but not absolute, assurance that the objectives of the system of internal control are met. The design of our control system reflects the fact that there are resource constraints, and that the benefits of such control system must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control failures and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the intentional acts of individuals, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part on certain assumptions about the likelihood of future events, and there can be no assurance that the design of any particular control will always succeed in achieving its objective under all potential future conditions.

## Risk factors

As filed, 134 characters.

There have been no material changes to the disclosures presented in our 2020 Annual Report on Form 10-K under *Item 1A. Risk Factors.*

Filed Aug 9, 2021.
Source: SEC EDGAR, the filing index for accession 0001723128-21-000032. Last ingested by Listed: Nov 10, 2026, 02:45 ET. No prices; not investment advice.
